CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma

This is a phase 1b, multicenter, feasibility/safety study of the dual delivery (administered through both intracavitary/intratumoral \[ICT\] and intraventricular \[ICV\] catheters) of CHM-1101, an autologous chlorotoxin-chimeric antigen receptor (CLTX-CAR) cell product, in participants with recurrent or progressive GBM. The investigational product is identified as CHM-1101 (CLTX(EQ)28ζ/CD19t+ CAR T cells). PRIMARY OBJECTIVE • To determine the recommended phase 2 dose (RP2D) for dual ICT and ICV delivery of CHM-1101 in participants with MMP2+ recurrent or progressive GBM. SECONDARY OBJECTIVES * To assess the feasibility and safety of dual delivery of CHM-1101. * To describe the persistence, expansion, immunogenicity, and phenotype of CHM-1101 and endogenous cells tumor cyst fluid (TCF), peripheral blood (PB), and cerebrospinal fluid (CSF). * In participants who receive at least 2 of the 3 planned doses of CHM-1101 in Cycle 1: * Estimate the progression-free survival (PFS) rates * Estimate the overall survival (OS) rates * To evaluate the disease response rate.